Drug Profile
AGTC 401
Alternative Names: AAV-CNB3; AAV-PR1.7-hCNGBco vector; AAV2/8; AAV2tYF-PR1.7-hCNGB3co; AAV9-PR1.7-hCNGB3co; ACHM B3; ACHM CNGB3; AGTC-401; CNGB3 gene-therapy-AGTC; rAAV2-hCNGB3; rAAV2tYF-PR1.7-hCNGB3Latest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Applied Genetic Technologies Corporation
- Developer Beacon Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action CNGB3 protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Colour vision defects
Most Recent Events
- 08 Feb 2022 Efficacy and adverse events data from a phase I/II trial of in Colour vision defects caused by mutations in CNGB3 gene released by Applied Genetic Technologies Corporation
- 09 Nov 2021 Interim adverse events data from a phase I/II trial in Colour vision defects released by Applied Genetic Technologies Corporation
- 29 Sep 2021 Applied Genetic Technologies Corporation plans to file End-of-Phase 2 (EOP2) meeting packet with the US FDA and expects feedback in the first half of 2022